Tandem Diabetes Care's stock rallied sharply after the company reported a significant profitability turnaround in its fourth-quarter earnings, demonstrating meaningful operational improvements across key financial metrics. The medical device manufacturer posted adjusted earnings of $0.01 per share against analyst consensus for a $0.08 loss, while revenue of $290.4 million exceeded the expected $277 million, driven by continued momentum in its insulin pump business.
The company's margin expansion represented a particularly notable development, with adjusted gross profit widening to 58% from 51% year-over-year, while adjusted operating profit swung to a $8.3 million gain compared with a $30.2 million loss in the prior-year period. This profitability inflection reflects management's cost optimization efforts and improved operational efficiency across the organization.
Looking ahead, Tandem provided 2026 guidance of $1.065 billion to $1.085 billion in revenue, projecting adjusted EBITDA margins of 5-6%. The company outlined plans to accelerate pump shipment growth at double-digit rates and introduce a new pay-as-you-go pricing model designed to enhance customer accessibility and support additional margin improvement.